Search

Displaying results 1591 - 1600 of 10000 in total
  1. Drug

    Eteplirsen

    go.drugbank.com/drugs/DB06014
    ApprovedInvestigational

    Eteplirsen was the first treatment for DMD approved by the FDA.[A244925] … [L40015] Duchenne muscular dystrophy is a rare genetic disorder characterized by progressive muscle deterioration and premature death most commonly due to respiratory or cardiac complications.

    Synonyms: N-dimethylphosphonamidate) RNA, dimethylamino)](2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a→5')(C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G),5'-(P-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonyl)-1-piperazinyl)-N,
  2. Drug

    Anastrozole

    go.drugbank.com/drugs/DB01217
    ApprovedInvestigational

    [L8863] Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and … Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer

  3. Drug

    Rilzabrutinib

    go.drugbank.com/drugs/DB17709
    ApprovedInvestigational

    [L53743] ITP is an autoimmune disorder characterized by low platelet count. … Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune

    Synonyms: -oxo-, (.alpha.e/z,3r)-, (e/z)-(r)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrile
  4. Drug

    Dihydroergocornine

    go.drugbank.com/drugs/DB11273
    Approved

    To know more about this mixture please refer to [DB01049]

  5. Drug

    Aducanumab

    go.drugbank.com/drugs/DB12274
    ApprovedInvestigational

    [L34420] Biogen enrolled patients in phase 3 clinical trials in 2015 but increased the size of the trials from 1350 patients to 1650 patients to maintain statistical power in the face of a high standard … [A235720] Development of aducanumab was discontinued in March 2019 when two phase 3 clinical trials did not pass futility analysis; however, Biogen sought FDA approval in October 2019 after reanalyzing

  6. Drug

    Estradiol benzoate

    go.drugbank.com/drugs/DB13953
    ApprovedVet approvedWithdrawn

    Estradiol benzoate is not currently available in Canada or the US. … As a pro-drug of estradiol, estradiol benzoate therefore has the same downstream effects within the body through binding to the Estrogen Receptor (ER) including ERα and ERβ subtypes, which are located

  7. Drug

    Testosterone propionate

    go.drugbank.com/drugs/DB01420
    ApprovedInvestigationalVet approvedWithdrawn

    Currently, this drug has been discontinued in humans, but the vet application is still available as an OTC.[L1160] … [T83] Testosterone propionate was developed initially by Watson labs, and FDA approved on February 5, 1974.

  8. Drug

    Magnesium cation

    go.drugbank.com/drugs/DB01378
    ApprovedInvestigationalNutraceuticalWithdrawn

    Milk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn. … When taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend

    Mixtures: MAGVEL 365 MG GRANÜL İÇEREN SAŞE, 10 ADET, MAGVEL 365 MG GRANÜL İÇEREN SAŞE, 20 ADET
  9. Drug

    Threonine

    go.drugbank.com/drugs/DB00156
    ApprovedInvestigationalNutraceutical

    An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.

    Mixtures: SmofKabiven Low Osmo peripher Emulsion zur Infusion, Vamin N
  10. Drug

    Tepotinib

    go.drugbank.com/drugs/DB15133
    ApprovedInvestigational

    Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February … Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma,[A228053] gastric cancers,[A228033] non-small cell lung cancer, and hepatocellular carcinoma.